Navigation Links
First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
Date:2/11/2009

ts are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether experimental pain models of pain, including the capsaicin model, are accurate in predicting efficacy of novel analgesics in early clinical trials, whether the results of any Phase II trial or other study of NGX426 will be consistent with the results of the study reported in this press release, whether TorreyPines will be able to complete any potential strategic or financing transaction on terms acceptable to TorreyPines' stockholders, how the volatile economic environment will affect TorreyPines' efforts to complete a strategic or financing transaction, whether TorreyPines' cash resources will be sufficient to fund operations as planned, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of the company's product candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of the company's product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of the company's product candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's product development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical tri
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Max Muscle Introduces First-Ever Probiotics Protein Bar
2. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
3. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
4. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
5. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
6. World's First Website for Patients to Share Diagnostic-Quality Medical Images
7. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
8. BioComp Pharma Launches First Generic Drug for Tindamax(R)
9. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
10. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting
11. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... -- BioNano Genomics, Inc., the leader in genome mapping, announced ... commercial officer. Salyer has more than 20 years of ... sciences. At BioNano, Salyer will oversee the commercialization of ... assemble a comprehensive view of complex genomes to help ... located in the United States , ...
(Date:3/26/2015)... 2015 PAREXEL International Corporation (Nasdaq: ... research organization , announced today that the ... acquire all of the business assets of privately-owned ... of specialized pharmacovigilance services, based in Chandigarh, ... assessment, monitoring, and prevention of adverse effects ...
(Date:3/26/2015)... Ale Gicqueau, Founder and President of Clinovo, ... at Align Technology, on “ Conducting Postmarket Registries - ... Global Conference and Exhibition on April 25th through April ... the poster presentation, Ale Gicqueau and Victor Chen will ... Registry, the requirements and resources to conduct the registry, ...
(Date:3/25/2015)... (PRWEB) March 26, 2015 Agnition announced ... episode of American Farmer, airing for the first time ... segment of American Farmer will explore the extremely important ... crop producers with a patented Microbial Catalyst™ technology that ... greater yields. The segment will air again on April ...
Breaking Biology Technology:BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2
... is largely transparent to the eye and, as it turns ... by scientists at Rice University and Rensselaer Polytechnic Institute (RPI) ... wet when clad by a single continuous layer of graphene ... in the online edition of Nature Materials , is ...
... Roche sets up co   - ... to HPV testing , ,In an innovative commercial ... pathology laboratory Unilabs-IHS, are collaborating to help make state-of-the ... to thousands of women in London and throughout the ...
... 2012   NeoStem, Inc. (NYSE Amex: NBS ... a focus on cell-based therapeutic development, today announced that its ... Phase 2 clinical trial for AMR-001 for preservation of ... President of its subsidiary, Progenitor Cell Therapy, LLC , ...
Cached Biology Technology:Water sees right through graphene 2HPV Testing for Cervical Cancer Risk Patients set to Increase 2HPV Testing for Cervical Cancer Risk Patients set to Increase 3Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease 2Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease 3Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease 4
(Date:3/24/2015)... 24, 2015   Crossmatch ™, a leading ... that its U.are.U ® 4500 Fingerprint Readers ... Bros . to achieve PCI compliance for Point-of-Sale ... to the POS terminal, protecting the retailer and ... breaches. With one-third of worldwide ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... of children with cancer, the hopeful news is that ... the bad newstreatments that enable survival often cause infertility. ... reached puberty currently have an opportunity to preserve their ... semen frozen and preserved in sperm banks. Younger boys, ...
... Rice University evolutionary biologists David Queller and Joan Strassmann argue ... between components, from the genetic level on up, give a ... a plant, a bacteria or a colony. Some ... as individuality or even membership in the same species, may ...
... of butterfly wings has inspired a 3.2m, three-year research ... of security, energy and the environment. The University of ... a collaborative contract to develop new technologies based on ... three years a team of physicists from the University ...
Cached Biology News:For young boys with cancer, testicular tissue banking may be option to preserve fertility 2For young boys with cancer, testicular tissue banking may be option to preserve fertility 3What is the meaning of 'one'? 2What is the meaning of 'one'? 3£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2
... Mouse monoclonal [3D12] to Lambda Free ... Mixture of light chains of human ... for independent constantly expressed epitope of ... dimer forms of free lambda chains ...
Request Info...
Cells are grown in triple flasks, roller bottles, or NUNC Factory. Viability and growth curves are generated from a parallel representative culture....
... Covance has generated hybridomas against ... to project initiation, you are provided ... consultation. Hybridoma cell lines developed by ... client. A typical hybridoma development project ...
Biology Products: